The findings offer promising support for progressing ADPO-002NP treatment to first-in-human Phase I clinical trials. Adipo Therapeutics LLC, a late-stage preclinical biopharmaceutical company focused on developing treatments for obesity and related metabolic disorders, recently presented findings from two studies at The Obesity Society’s annual meeting in San Antonio. The studies were designed to evaluate the […]
